Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Kinder, gentler procedure gives superior results for stem cell transplants

14.12.2004


An improved stem cell transplant regimen that is well-tolerated and has a high success rate has been developed by researchers at Washington University School of Medicine in St. Louis. The procedure holds promise for treatment of blood and bone marrow disorders, immune dysfunction and certain metabolic disorders.

Designed for transplants that replace a patient’s bone marrow with stem cells from donor marrow, peripheral blood or umbilical cord blood, the procedure allows early recovery of immune function, nearly eliminates transplant rejection, and decreases the incidence and severity of "graft vs. host disease," a common complication in transplants.

Termed a "reduced-intensity" protocol, in pediatric patients it may minimize damage to sensitive growing tissues like the brain and reproductive organs.



The pilot study of the procedure is reported in the journal Bone Marrow Transplantation. It is available through advance online publication on Dec. 13 and will appear in a future print issue.

The regimen was administered to 11 pediatric and 5 adult patients at St. Louis Children’s and Barnes-Jewish hospitals and the Children’s Hospital of New Orleans who had non-malignant bone marrow or metabolic disorders such as sickle cell anemia, thalassemia or Hurler’s syndrome. Symptoms and disease parameters stabilized or improved in all patients that underwent successful transplants.

In a successful stem cell transplant, the donor stem cells become permanently established, or engrafted, in the patient’s bone marrow and continually produce healthy blood cells. To prevent the host immune system from destroying the foreign stem cells, physicians administer a pretransplant immune suppressing treatment.

"We wanted an approach that would effectively knock out the patient’s immune system to let the transplanted cells engraft, but then allow immune function to recover quickly," says study leader Shalini Shenoy, M.D., assistant professor of pediatrics and faculty member of the Siteman Cancer Center.

A key innovation in this study changes the timing of administering a powerful pretransplant conditioning drug. The drug, Campath-1H, targets and destroys several vital immune system components. Previous studies used Campath-1H in higher doses and gave the drug at transplant time. With such dosing, Campath stayed in the body for up to 56 days after the transplant.

"We give a short, three-day, lower-dose treatment of Campath, three weeks in advance of transplant," Shenoy says. "As a result, we ensure that Campath levels are lower by the time of transplant to help establish donor cells and allow early recovery of immune function."

With standard transplant protocols, immune function may not fully recover for a year or more, and during this time, the patient is highly susceptible to life-threatening infections. In this study, the patients’ immune function showed significant recovery by six months, and no major infections were encountered after this period.

Fourteen of the 16 patients had successful bone marrow engraftment of the donor stem cells and only one experienced late graft rejection, an unusually high rate of success according to Shenoy. Furthermore, the grafts took hold quickly. Donor stem cells had established in the bone marrow completely at one month, contrasting with other reduced-intensity protocols where donor engraftment is gradual and often takes many months.

The protocol also reduced the incidence and severity of graft vs. host disease, which occurs when transplanted immune cells attack various cells in the body. For the majority of patients who experienced graft vs. host disease, the symptoms were limited to the skin and were controlled with treatments that were later successfully withdrawn.

To minimize damage to still-growing tissues such as the brain and reproductive organs in pediatric patients, the protocol uses smaller doses of standard conditioning chemotherapeutic agents.

"In the past, physicians had to accept the potential for brain damage or sterility in pediatric patients treated with chemotherapy," Shenoy says. "We’re trying to provide treatments that protect developing tissues. We’ve had our first pregnancy and normal delivery in one of our stem cell transplant patients, so we think the protocol offers some hope."

Next, Shenoy plans to evaluate whether changing parameters and further reducing chemotherapy doses would enhance the protocol’s effectiveness. She will also conduct studies targeted at sickle cell anemia and chronic myelogenous leukemia to explore the potential for successful transplants in children with these disorders.

Gwen Ericson | EurekAlert!
Further information:
http://www.wustl.edu

More articles from Life Sciences:

nachricht Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory

nachricht Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>